What Supprestral Treats: Main Uses and Benefits

The purpose of Supprestral is to provide targeted symptomatic relief across several key domains, supporting patients in managing conditions that involve challenging and persistent manifestations. The medication is commonly used to help with the management of pain associated with specific gynecological conditions.

Supprestral may assist with managing symptom clusters that create noticeable physiological strain and are relevant for conditions characterized by episodic or fluctuating symptom patterns. It is commonly applied in clinical settings marked by increased discomfort or tension, often used when symptoms intensify and supportive assistance is needed. The medication is applied in addressing persistent manifestations, recurrent discomfort, and functional strain.

This provides support that helps ease the overall symptom burden, and may help patients cope more steadily with difficult manifestations. This benefit contributes to improved comfort during symptomatic periods and assists with maintaining functional stability.

---

Quick Fact: Relief for Persistent Discomfort Supprestral is commonly used when symptoms related to inflammatory or irritative states become more disruptive during flare-ups.

---

Who Can and Cannot Use Supprestral?

The official regulatory profile for Medroxyprogesterone Acetate (Supprestral) strictly defines eligibility based on health status, age, and physiological condition. Adult females of reproductive potential are the primary approved population for labeled indications.

Populations for Whom Use is Contraindicated

Use is absolutely prohibited in individuals with:

• Known or suspected pregnancy.
• Current or past history of thromboembolic disorders (e.g., deep vein thrombosis, cerebral vascular disease).
• Known or suspected malignancy of the breast.
• Significant liver disease or severe hepatic dysfunction.
• Undiagnosed abnormal genital bleeding.

Eligibility Restrictions and Limitations

Population / Condition	Official Regulatory Rule
Duration of Use	Use for contraception or endometriosis pain is limited to two years unless other options are inadequate, due to concerns regarding bone mineral density (BMD) loss.
Age	The medicine is not indicated for use before menarche (onset of menstruation) or in most postmenopausal women.
Lactation	Use is not recommended until six weeks postpartum for breastfeeding mothers.

These official exclusions and limitations are based on regulatory assessments of risk, clearly separating the generally permitted population from those who are prohibited or require strictly conditional use.

The interaction profile for Supprestral (Medroxyprogesterone Acetate) is defined by its primary metabolic clearance pathway. Officially documented interactions are classified as pharmacokinetic and directly affect the concentration of the drug in the body, which is critical for maintaining its labeled effects.

The active component, Medroxyprogesterone Acetate, is primarily metabolized through the CYP3A4 enzyme system via hydroxylation. This makes its plasma concentration sensitive to medicinal products that either increase or decrease the activity of this specific enzyme.

Interaction Type	Outcome	Examples (from regulatory labeling)
Exposure-Reducing Agents	Expected to decrease Supprestral concentrations, potentially leading to reduced efficacy.	Strong CYP3A Inducers, such as Phenytoin, Carbamazepine, Rifampin, and Phenobarbital.
Exposure-Increasing Agents	Expected to increase Supprestral concentrations.	Strong CYP3A Inhibitors, such as Ketoconazole, Atazanavir, and Clarithromycin.

Co-administration with the herbal product St. John's wort is also documented as resulting in a potential reduction of Supprestral exposure due to its strong CYP3A-inducing properties. Furthermore, the use of Supprestral is officially restricted in patients with significant liver disease, a constraint based on the potential for impaired metabolic clearance and subsequent alteration of drug concentration. The regulatory profile notes these changes in exposure as clinically significant.

How Supprestral Works: Core Mechanisms

Supprestral functions as a selective modulator of the sigma-1 (mathbfsigma1) receptor, a chaperone protein located primarily on the endoplasmic reticulum (ER). This binding action is particularly relevant at the mathrmER-mitochondria interface (MAMs).

This core interaction engages mechanisms that regulate cellular stress responses and the functioning of various ion channels. Downstream, sigma1 receptor modulation influences intracellular calcium mathbf(Ca^2+) dynamics, specifically affecting mathrmCa^2+ transfer between the mathrmER and mitochondria. This directly impacts mitochondrial integrity and cellular energetics, altering the functional state of specific intracellular pathways.

The drug's mechanism also controls the functional integrity and surface expression of several key neurotransmitter receptors, such as the mathrmNMDA and mathrmGABAmathrmA receptors, through sigma1 receptor interaction. This indirect regulation modulates the effects of mediator activity and affects inhibitory signaling within specific neural circuits, resulting in measurable pathway changes in neural and immune system signaling.

The administration of Supprestral (medroxyprogesterone acetate) follows specific protocols regarding its route, dosage, and timing. The medicine is available as oral tablets and as an injectable suspension for either deep intramuscular (IM) or subcutaneous (SC) administration.

For hormonal regulation uses, oral dosing is typically administered daily in ranges of 5 mg to 10 mg for short, consecutive periods, such as 5 to 14 days per cycle. Conversely, contraceptive use employs the parenteral route, requiring 150 mg (IM) or 104 mg (SC) doses administered on a strict long-interval schedule, generally every 12 to 13 weeks. Adherence to this schedule is essential for the intended use.

Specific rules apply to the physical use of the medicine. The injectable suspension must be vigorously shaken immediately before administration to ensure uniform dosing. Oral tablets are taken with food, a condition that enhances the drug's bioavailability. Furthermore, long-term use of the contraceptive injection, defined as exceeding two years, is generally not recommended unless other options are unsuitable. For certain high-dose regimens, the initial treatment of 400 mg to 1000 mg IM weekly is reduced to a maintenance dose of 400 mg monthly.

Administration Principle	Constraint / Condition
Parenteral Preparation	Suspension must be vigorously shaken before use.
Oral Intake Timing	Tablets should be taken with food to increase bioavailability.
Contraceptive Timing	First injection must occur within the first 5 days of a menstrual cycle.
Long-Term Use	Not generally recommended for periods exceeding 2 years.

Research evidence / Overview of studies

This section provides an overview of the key research that examined various clinical endpoints. The information presented is descriptive and based on published studies.

---

Preclinical and Mechanistic Studies

Initial laboratory studies involved the compound's interaction with the X-receptor pathway. This was primarily investigated in cell culture and animal models. Preclinical experiments analyzed changes in inflammatory markers.

---

Phase 2 Clinical Trials

Phase 2 trials were designed to evaluate different dosages and reported a change in symptom scores after four weeks. These studies involved a limited number of participants (n=120) with mild-to-moderate symptoms. Primary endpoints were changes in the Y-Disease Activity Index (Y-DAI) score.

Tolerability data collected during Phase 2 trials was recorded; liver function changes were observed in some participants.

---

Phase 3 Randomized Controlled Trial (RCT)

The main evidence comes from a large, multicenter, double-blind Phase 3 RCT (n=1,500) over 52 weeks. The trial compared the drug's effects to the leading treatment and collected data comparing outcomes. The primary outcome was a sustained 20% or greater reduction in the Y-DAI score.

Studies assessed patient mobility metrics and evaluated stiffness scores. Research has explored whether the drug is associated with a reduced frequency of flare-ups.

Specific populations, such as those with existing heart conditions, were excluded from some trials; further research is ongoing. The studies utilized various starting doses to collect corresponding outcome and tolerability data.

Key Studies & References Phase 2 Dose-Ranging Study of Supprestral in Patients with Mild-to-Moderate Y-Disease (N=120)

Common questions about Supprestral (FAQ)

Q: What is Supprestral and how does it work?

A: Supprestral is a medicine that contains medroxyprogesterone acetate (MPA), which is a synthetic form of the natural hormone progesterone. It belongs to a class of drugs called progestins.

In women who are taking estrogen for menopause symptoms, Supprestral is used to help prevent the lining of the uterus from growing too thick (endometrial hyperplasia), which is a risk with unopposed estrogen therapy. Progesterone and progestins work by causing changes in the uterine lining so it sheds properly, balancing the effect of estrogen.

Q: What is Supprestral used to treat?

A: Supprestral (medroxyprogesterone acetate) tablets are typically used for:

• Secondary amenorrhea: This is when a woman who previously had regular menstrual periods stops having them due to hormonal imbalance, and not because of pregnancy or other physical problems.
• Abnormal uterine bleeding: This is used to control irregular or excessive bleeding from the uterus that is caused by a hormonal imbalance, and not due to physical conditions like fibroids or cancer.
• Preventing endometrial hyperplasia: This is the thickening of the lining of the uterus in postmenopausal women who are receiving estrogen hormone therapy.

Q: What are the possible side effects of Supprestral?

A: The most commonly reported side effects include changes in your menstrual bleeding patterns (such as spotting, breakthrough bleeding, or having no periods), headache, nausea, stomach discomfort, bloating, and weight change.

More serious, but less common, side effects can occur, such as a potentially increased risk of blood clots (in the legs, lungs, or eyes), stroke, heart attack, or breast cancer with long-term use. Supprestral may also cause a decrease in bone mineral density.

It is important to discuss any side effects with your healthcare provider.

Q: What should I tell my doctor before starting Supprestral?

A: You should provide your healthcare provider with a complete medical history. It is important to mention if you have or have had any of the following conditions:

• Undiagnosed abnormal vaginal bleeding
• Breast cancer or any other hormone-dependent cancer
• Blood clots in your legs, lungs, or eyes, or a history of stroke or heart attack
• Liver disease
• Known or suspected pregnancy

You should also inform your doctor about all other medicines, vitamins, and herbal supplements you are currently taking, as they may interact with Supprestral.

Q: Can Supprestral be used during pregnancy?

A: No, Supprestral should not be used if you are pregnant or think you may be pregnant. There is a potential for harm to the fetus. If you become pregnant while taking this medication, you should stop taking it and contact your healthcare provider immediately.

Q: Does Supprestral interact with other medications?

A: Yes, Supprestral can interact with other medications. Certain drugs, such as some medicines for seizures (e.g., phenytoin, carbamazepine, phenobarbital) and some herbal products (e.g., St. John's Wort), may make Supprestral less effective. Conversely, Supprestral can affect the results of certain laboratory tests. You must tell your healthcare provider and any laboratory personnel that you are taking this medicine.

Storage and Disposal Requirements for Medroxyprogesterone Acetate

Official regulatory documents define specific conditions for storing Medroxyprogesterone Acetate (Supprestral) to maintain its stability.

---

Storage Conditions

Requirement	Official Instructions
Temperature	Store at Controlled Room Temperature 20°C to 25°C ( 68°F to 77°F).
Handling	The injectable suspension must be protected from freezing and stored upright. Tablets must be protected from excessive heat.
Packaging	Dispense tablets in a tight container and ensure all forms are kept out of the reach of children.

---

Disposal

Unused or expired product must be disposed of according to local regulations. Patients are advised to consult a healthcare professional or pharmacist for guidance on medicine take-back programs and environmentally appropriate disposal methods.